Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TARA | US
-0.02
-0.99%
Healthcare
Biotechnology
30/06/2024
30/08/2024
2.00
2.02
2.03
1.90
Protara Therapeutics Inc. a clinical-stage biopharmaceutical company engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002 an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics Inc. and changed its name to Protara Therapeutics Inc. in May 2020. The company is headquartered in New York New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
47.2%1 month
51.2%3 months
57.5%6 months
71.8%-
-
0.45
0.05
0.05
0.74
-
-
-43.90M
41.26M
41.26M
-
-
-
-
-45.91
13.97
12.12
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.40
Range1M
0.52
Range3M
1.22
Rel. volume
0.86
Price X volume
299.80K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CALC | CALC | Biotechnology | 4.17 | 44.83M | -3.02% | n/a | 0.00% |
Aadi Bioscience Inc | AADI | Biotechnology | 1.81 | 44.55M | 3.43% | n/a | 1.34% |
CARM | CARM | Biotechnology | 1.07 | 44.45M | -1.83% | n/a | 0.00% |
Lantern Pharma Inc. | LTRN | Biotechnology | 4.09 | 44.03M | 1.24% | n/a | 0.71% |
Syros Pharmaceuticals Inc | SYRS | Biotechnology | 1.64 | 43.97M | -1.20% | n/a | -954.99% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.6006 | 43.82M | 0.43% | n/a | 0.00% |
PASSAGE BIO INC. | PASG | Biotechnology | 0.7006 | 43.27M | -5.96% | n/a | 0.00% |
OncoCyte Corporation | OCX | Biotechnology | 3.14 | 41.98M | -0.09% | n/a | 16.15% |
NextCure Inc | NXTC | Biotechnology | 1.47 | 41.12M | -6.37% | n/a | 7.21% |
Elicio Therapeutics Inc. | ELTX | Biotechnology | 3.8 | 40.94M | -5.00% | 4.13 | -388.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.74 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 0.45 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 57.46 | 76.13 | Lower Risk |
Debt to Equity | 0.05 | -2.05 | Expensive |
Debt to Assets | 0.05 | 0.25 | Cheaper |
Market Cap | 41.26M | 4.04B | Emerging |